116 related articles for article (PubMed ID: 38279433)
21. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.
Kapodistria K; Tsilibary EP; Kotsopoulou E; Moustardas P; Kitsiou P
J Cell Mol Med; 2018 Jun; 22(6):2970-2980. PubMed ID: 29524296
[TBL] [Abstract][Full Text] [Related]
22. Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE
Zhang K; Li R; Matniyaz Y; Yu R; Pan J; Liu W; Wang D
Biochem Pharmacol; 2024 May; 223():116170. PubMed ID: 38548245
[TBL] [Abstract][Full Text] [Related]
23. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.
McLean BA; Wong CK; Kabir MG; Drucker DJ
Mol Metab; 2022 Dec; 66():101641. PubMed ID: 36396031
[TBL] [Abstract][Full Text] [Related]
25. Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R.
Li Z; Li S; Wang N; Xue P; Li Y
Biomed Pharmacother; 2020 Oct; 130():110523. PubMed ID: 32702632
[TBL] [Abstract][Full Text] [Related]
26. Parthenolide Inhibits the Proliferation of MDA-T32 Papillary Thyroid Carcinoma Cells in Vitro and in Mouse Tumor Xenografts and Activates Autophagy and Apoptosis by Downregulation of the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Signaling Pathway.
Li C; Zhou Y; Cai Y; Shui C; Liu W; Wang X; Jiang J; Zeng D; Gui C; Sun R
Med Sci Monit; 2019 Jul; 25():5054-5061. PubMed ID: 31322140
[TBL] [Abstract][Full Text] [Related]
27. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
Chiu WY; Shih SR; Tseng CH
Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
[TBL] [Abstract][Full Text] [Related]
28. Ellagic acid inhibits cell proliferation, migration, and invasion of anaplastic thyroid cancer cells via the Wnt/β-catenin and PI3K/Akt pathways.
Meng X; Cui Z; Shi H; Ma X; Li W; Liu X; Jiang Y
Acta Biochim Pol; 2023 Feb; 70(1):109-115. PubMed ID: 36773307
[TBL] [Abstract][Full Text] [Related]
29. Artesunate inhibits proliferation, migration, and invasion of thyroid cancer cells by regulating the PI3K/AKT/FKHR pathway.
Xu Z; Liu X; Zhuang D
Biochem Cell Biol; 2022 Feb; 100(1):85-92. PubMed ID: 34797728
[TBL] [Abstract][Full Text] [Related]
30. Effects of insulin analogs and glucagon-like peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer.
He L; Zhang S; Zhang X; Liu R; Guan H; Zhang H
Onco Targets Ther; 2017; 10():5621-5631. PubMed ID: 29200876
[TBL] [Abstract][Full Text] [Related]
31. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
Li Y; Bader M; Tamargo I; Rubovitch V; Tweedie D; Pick CG; Greig NH
J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
[TBL] [Abstract][Full Text] [Related]
32. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
[TBL] [Abstract][Full Text] [Related]
33. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.
Nakamura T; Ito T; Uchida M; Hijioka M; Igarashi H; Oono T; Kato M; Nakamura K; Suzuki K; Jensen RT; Takayanagi R
Lab Invest; 2014 Jan; 94(1):63-78. PubMed ID: 24217090
[TBL] [Abstract][Full Text] [Related]
34. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.
Madsen LW; Knauf JA; Gotfredsen C; Pilling A; Sjögren I; Andersen S; Andersen L; de Boer AS; Manova K; Barlas A; Vundavalli S; Nyborg NC; Knudsen LB; Moelck AM; Fagin JA
Endocrinology; 2012 Mar; 153(3):1538-47. PubMed ID: 22234463
[TBL] [Abstract][Full Text] [Related]
35. Effect of hCMSCs and liraglutide combination in ALI through cAMP/PKAc/β-catenin signaling pathway.
Feng Y; Wang L; Ma X; Yang X; Don O; Chen X; Qu J; Song Y
Stem Cell Res Ther; 2020 Jan; 11(1):2. PubMed ID: 31900217
[TBL] [Abstract][Full Text] [Related]
36. Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt.
Rupprecht LE; Mietlicki-Baase EG; Zimmer DJ; McGrath LE; Olivos DR; Hayes MR
Am J Physiol Endocrinol Metab; 2013 Sep; 305(6):E751-9. PubMed ID: 23900416
[TBL] [Abstract][Full Text] [Related]
37. GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning.
Wang J; Zhou Y; Long D; Wu Y; Liu F
Biochem Biophys Res Commun; 2023 Jul; 664():142-151. PubMed ID: 37167707
[TBL] [Abstract][Full Text] [Related]
38. Liraglutide Attenuates Restenosis After Vascular Injury in Rabbits With Diabetes Via the TGF-β/Smad3 Signaling Pathway.
Ding HX; Dong NX; Zhou CX; Wang FJ; Xing N; Ma HF; Hou L
Altern Ther Health Med; 2022 Sep; 28(6):22-28. PubMed ID: 35751893
[TBL] [Abstract][Full Text] [Related]
39. Protective action of liraglutide in beta cells under lipotoxic stress via PI3K/Akt/FoxO1 pathway.
Shao S; Nie M; Chen C; Chen X; Zhang M; Yuan G; Yu X; Yang Y
J Cell Biochem; 2014 Jun; 115(6):1166-75. PubMed ID: 24415347
[TBL] [Abstract][Full Text] [Related]
40. Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/ mTOR/Caspase-3 and PI3K/Akt/GSK3β/Caspase-3 Signaling Pathways.
Yao M; Zhang J; Li Z; Bai X; Ma J; Li Y
Front Med (Lausanne); 2021; 8():630962. PubMed ID: 33681258
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
